论文部分内容阅读
目的研究趋化因子配体19(CCL19)及其受体趋化因子受体7(CCR7)在风湿性二尖瓣狭窄(RMS)患者瓣膜组织中的表达、分布特点和细胞定位。方法采用GeneChip Human Gene1.0ST基因芯片和免疫组织化学染色法检测RMS病变二尖瓣瓣膜(A组,16例)和正常瓣膜(B组,3例)中CCL19和CCR7的表达情况。结果 A组CCL19和CCR7均高表达;其中,CCL19主要分布在炎症细胞区域,CCR7主要在瓣膜间质细胞表达。而B组中CCL19和CCR7均无明显表达。结论 RMS患者二尖瓣瓣膜组织中CCL19主要表达于浸润的炎症细胞,CCR7表达于瓣膜间质细胞,两者相互作用参与瓣膜的病理过程。
Objective To investigate the expression, distribution and cellular localization of chemokine ligand 19 (CCL19) and its receptor chemokine receptor 7 (CCR7) in the valve tissue of patients with rheumatic mitral stenosis (RMS). Methods The gene expression of CCL19 and CCR7 in mitral valve (group A, n = 16) and normal valve (group B, n = 3) were detected by GeneChip Human Gene 1.0ST gene chip and immunohistochemical staining. Results The expression of CCL19 and CCR7 in group A were highly expressed. Among them, CCL19 mainly distributed in the inflammatory cell area, and CCR7 mainly expressed in the valve interstitium. However, no significant expression of CCL19 and CCR7 in group B was observed. Conclusions CCL19 in mitral valve tissue of RMS patients is mainly expressed in infiltrating inflammatory cells, and CCR7 is expressed in valve interstitial cells. The interaction between them is involved in the pathological process of the valve.